ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 16 OCTOBER 2026 Response to ASX Price Query Amplia Therapeutics Limited (ASX:ATX;) (“Amplia” or the “Company”) refers to the Price Query letter received from ASX Supervision today. Amplia provides the following responses as requested: 1. Amplia is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities; 2. Not applicable; 3. Amplia is not aware of any other explanation for the recent trading in its securities; 4. Amplia is complying with the Listing Rules and, in particular, Listing Rule 3.1; 5. Amplia’s responses above have been authorised and approved by the Managing Director who has delegated authority from the Board to respond to the ASX on disclosure matters. Andrew J. Cooke Company Secretary Company Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Investor Contact: Hannah Howlett, Titch Comms Hannah@titchcomms.com.au +61 450 648 064 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. ASX Limited [[Listings]] ASX Customer Service Centre 131 279 | asx.com.au #11157545v1 16 October 2026 Mr Andrew Cooke Company Secretary Amplia Therapeutics Limited Level 5 90 William Street Melbourne VIC 3000 By email Dear Mr Cooke Amplia Therapeutics Limited (‘ATX’): Price Query ASX refers to the following: A. The change in the price of ATX’s securities from close of $0.100 on 15 October 2026 to a low of $0.079 today at the time of writing. B. The significant increase in the volume of ATX’s securities traded today. Request for information In light of this, ASX asks ATX to respond separately to each of the following questions and requests for information: 1. Is ATX aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities? 2. If the answer to question 1 is “yes”. (a) Is ATX relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in ATX’s securities would suggest to ASX that such information may have ceased to be confidential and therefore ATX may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation. (b) Can an announcement be made immediately? Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below). (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made? 3. If the answer to question 1 is “no”, is there any other explanation that ATX may have for the recent trading in its securities? 4. Please confirm that ATX is complying with the Listing Rules and, in particular, Listing Rule 3.1. 5. Please confirm that ATX’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of ATX with delegated authority from the board to respond to ASX on disclosure matters. When and where to send your response This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 2:30 PM AEDT on Friday, 16 October 2026 2/2 ASX Customer Service Centre 131 279 | asx.com.au #11157545v1 You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ATX’s obligation is to disclose the information ‘immediately’. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require ATX to request a trading halt immediately. Your response should be sent by e-mail to ListingsComplianceSydney@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform. Trading halt If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in ATX’s securities under Listing Rule 17.1. If you wish to request a trading halt, you must tell us: • the reasons for the trading halt; • how long you want the trading halt to last; • the event you expect to happen that will end the trading halt; • that you are not aware of any reason why the trading halt should not be granted; and • any other information necessary to inform the market about the trading halt, or that we ask for. We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 Trading Halts and Voluntary Suspensions. Suspension If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in ATX’s securities under Listing Rule 17.3.1. Listing Rules 3.1 and 3.1A In responding to this letter, you should have regard to ATX’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B. It should be noted that ATX’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter. Release of correspondence between ASX and entity ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A. The usual course is for correspondence to be released to the market. Regards ASX Supervision